Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H-Biota Kolicare is an over-the-counter probiotic dietary supplement developed by AB-Biotics (acquired by Kaneka) and marketed by H-biota. It is specifically formulated for newborns and infants up to 3 years of age to prevent and treat infant colic, support digestive health, and promote healthy gut microbiota development. The product contains a patented, clinically proven synergistic blend of two probiotic strains: *Bifidobacterium longum* KABP 042 (CECT 7894) and *Pediococcus pentosaceus* KABP 041 (CECT 8330), suspended in refined sunflower oil and enriched with Vitamin D3 (cholecalciferol). The probiotic strains work by adhering to the intestinal epithelium, reinforcing the gut barrier, inhibiting opportunistic pathogens associated with colic, and reducing gut inflammation, while Vitamin D3 supports the normal function of the immune system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on H-Biota Kolicare.